These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 20852385)

  • 1. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.
    Marubayashi S; Koppikar P; Taldone T; Abdel-Wahab O; West N; Bhagwat N; Caldas-Lopes E; Ross KN; Gönen M; Gozman A; Ahn JH; Rodina A; Ouerfelli O; Yang G; Hedvat C; Bradner JE; Chiosis G; Levine RL
    J Clin Invest; 2010 Oct; 120(10):3578-93. PubMed ID: 20852385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.
    Bhagwat N; Koppikar P; Keller M; Marubayashi S; Shank K; Rampal R; Qi J; Kleppe M; Patel HJ; Shah SK; Taldone T; Bradner JE; Chiosis G; Levine RL
    Blood; 2014 Mar; 123(13):2075-83. PubMed ID: 24470592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation.
    Pandey G; Kuykendall AT; Reuther GW
    Blood Cancer J; 2022 Jan; 12(1):13. PubMed ID: 35082276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
    Ambati SR; Lopes EC; Kosugi K; Mony U; Zehir A; Shah SK; Taldone T; Moreira AL; Meyers PA; Chiosis G; Moore MA
    Mol Oncol; 2014 Mar; 8(2):323-36. PubMed ID: 24388362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy.
    Li HK; Matsumoto Y; Furusawa Y; Kamada T
    J Radiat Res; 2016 Sep; 57(5):572-575. PubMed ID: 27242340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
    Berdeja J; Palandri F; Baer MR; Quick D; Kiladjian JJ; Martinelli G; Verma A; Hamid O; Walgren R; Pitou C; Li PL; Gerds AT
    Leuk Res; 2018 Aug; 71():82-88. PubMed ID: 30025280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future therapies for the myeloproliferative neoplasms.
    Scherber R; Mesa RA
    Curr Hematol Malig Rep; 2011 Mar; 6(1):22-7. PubMed ID: 21080242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
    Griesshammer M; Sadjadian P
    Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
    Quintás-Cardama A; Verstovsek S
    Cancer; 2012 Feb; 118(4):870-7. PubMed ID: 21766300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice.
    Debeurme F; Lacout C; Moratal C; Bagley RG; Vainchenker W; Adrian F; Villeval JL
    J Cell Mol Med; 2015 Nov; 19(11):2564-74. PubMed ID: 26176817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.
    Weigert O; Lane AA; Bird L; Kopp N; Chapuy B; van Bodegom D; Toms AV; Marubayashi S; Christie AL; McKeown M; Paranal RM; Bradner JE; Yoda A; Gaul C; Vangrevelinghe E; Romanet V; Murakami M; Tiedt R; Ebel N; Evrot E; De Pover A; Régnier CH; Erdmann D; Hofmann F; Eck MJ; Sallan SE; Levine RL; Kung AL; Baffert F; Radimerski T; Weinstock DM
    J Exp Med; 2012 Feb; 209(2):259-73. PubMed ID: 22271575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1 study of the Janus kinase 2 (JAK2)
    Verstovsek S; Mesa RA; Salama ME; Li L; Pitou C; Nunes FP; Price GL; Giles JL; D'Souza DN; Walgren RA; Prchal JT
    Leuk Res; 2017 Oct; 61():89-95. PubMed ID: 28934680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.
    Caldas-Lopes E; Cerchietti L; Ahn JH; Clement CC; Robles AI; Rodina A; Moulick K; Taldone T; Gozman A; Guo Y; Wu N; de Stanchina E; White J; Gross SS; Ma Y; Varticovski L; Melnick A; Chiosis G
    Proc Natl Acad Sci U S A; 2009 May; 106(20):8368-73. PubMed ID: 19416831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.
    Kale Ş; Korcum AF; Dündar E; Erin N
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Feb; 393(2):253-262. PubMed ID: 31522240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.
    Stein BL; Tiu RV
    J Interferon Cytokine Res; 2013 Apr; 33(4):145-53. PubMed ID: 23570380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
    Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
    PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.
    Meyer SC
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):627-642. PubMed ID: 28673392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.
    Patel AB; Vellore NA; Deininger MW
    Clin Cancer Res; 2016 Mar; 22(5):1037-47. PubMed ID: 26933174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.